📢 Pleased to share this work Nature Portfolio 👉rdcu.be/dkbVo Our insilico model can predict gefitinib efficacy in a EGFR+ NSCLC virtual population Application to next gen EGFRTKI and new antiEGFR therapy are ongoing Stay tuned! @novadiscovery OncoAlert

a summary of our work is available 👇 cancercommunity.nature.com/posts/knowledg…

Pleased to share this article BMC #BMCBioinformatics : bmcbioinformatics.biomedcentral.com/articles/10.11… We present in this paper how using a combination of metrics could be more relevant, with the objective of validating a given model and its predictions within a specific context of use.

📢FLAURA2 will be presented on Monday #WCLC23 IASLC We share an in silico prediction of FLAURA2 outcomes, using #jinko @novadiscovery platform We predict: Time To Progression HR of 0.60, mTTP of 17.3 mo. in osi arm and of 25.9 in osi+chemo arm OncoAlert #LCSM our data🧵(1/9)👇

Let's see in a few hours if our FLAURA 2 outcomes prediction is close to the real ones! x.com/MDuruisseaux/s…

@canceroCLARA Lyonbiopôle Auvergne-Rhône-Alpes Merci au Lyonbiopôle Auvergne-Rhône-Alpes et au @canceroCLARA de m'avoir invité à discuter de la thématique passionnante du développement des biomarqueurs en oncologie en compagnie des Prs Brevet et Saintigny

1re mondiale 🌍 Les travaux sur l’intelligence artificielle menés par les Hospices Civils de Lyon & @novadiscovery ouvrent la voie à une nouvelle conception des essais cliniques pharmaceutiques 📊 La modélisation d’un essai clinique de phase 3 a permis, pour la première fois au

Superbe ! Bravo Michael Duruisseaux @novadiscovery #TeamHCL URCOT / Hospices Civils de Lyon 🫁🔬

ℹ️ teamhcl.chu-lyon.fr/novadiscovery-… HCL | Recherche en santé @novadiscovery Michael Duruisseaux URCOT / Hospices Civils de Lyon 🫁🔬 #teamHCL

Merci France 3 Rhône-Alpes d'avoir relayé notre prédiction de résultat d'essais thérapeutiques par une méthode d'intelligence artificielle conçue par la biotech lyonnaise @novadiscovery exemple de partenariat CHU HCL - Hospices Civils de Lyon et biotech = innovation de rupture france3-regions.francetvinfo.fr/auvergne-rhone…

Une innovation lyonnaise réussit à prédire les résultats d'un essai clinique de phase III HCL - Hospices Civils de Lyon @novadiscovery via @hospimedia #IA #clinicaltrials hospimedia.fr/actualite/arti…

Sharing great feedback from a Jinkō user✨

🫁 Delighted to share our latest paper! Dive into the forefront of NSCLC math. modeling research and discover the latest advancements from the @novadiscovery team, insightfully co-authored by Michael Duruisseaux. Immerse yourself in the scientific details here: mdpi.com/2227-9059/12/3…

Fruitful collaboration with @novadiscovery and Michael Duruisseaux HCL - Hospices Civils de Lyon Have a great one at #ASCO24 sharing those impressive results! ASCO

#ASCO24 Say hi and stop by poster #478. In silico prediction using mechanistic models can predict actual clinical trial data. Can we use this tool to build phase III trial statistical assumption? @novadiscovery HCL - Hospices Civils de Lyon

ASCO 2024! 🚀 Claudio Monteiro and Prof. Michael Duruisseaux presented our poster at the American Society of Clinical Oncology. Our in silico approaches with jinkō have reached maturity, accelerating drug development and making it more efficient and cost-effective.

📢 Création de la nouvelle structure d'essai précoce HCL - Hospices Civils de Lyon EPSILYON (Early Phase StudIes in LYON), labellisée CLIP2 Institut national du cancer 👉recherche.chu-lyon.fr/label-clip2 Honoré de coordonner la nouvelle unité d'essai précoce tumeurs solides du GH Est

🥁 hot of the press new piece of work from our Lab SLX4 and XPF, two proteins involved in DNA repair, are involved in pro-tumoral properties, and may be interesting targets in solid tumors 🙏 Ligue cancer Rhône article available 👇 sciencedirect.com/science/articl… Cancer Research Center of Lyon HCL - Hospices Civils de Lyon